Dihydralazine sulphate

Dihydralazine sulphate (CAS No.: 7327-87-9) is a synthetic small molecule of the hydrazinophthalazine class that is broadly categorized as a vascular pharmacology and genetic toxicology research tool in life sciences and drug discovery workflows, with a functional background centered on direct vasorelaxant activity in resistance vessels and on DNA reactive mutagenic behavior observed in experimental systems; mechanistically, available evidence supports reduction of systemic vascular resistance through direct action on vascular smooth muscle, with downstream hemodynamic effects that are commonly associated with compensatory increases in cardiac output and heart rate in preclinical physiology models, while genotoxicity studies indicate a mixed gene mutation profile including direct acting mutagenicity, induction of DNA fragmentation in mouse tissues such as lung, kidney, and spleen, elevation of sister chromatid exchange in mouse bone marrow cells, and selective cytotoxicity in DNA repair deficient bacterial strains, supporting use in studies of genome stability, stress response, and structure activity relationships within hydrazine related chemotypes; because robust target resolved binding constants are not consistently defined for this compound, it is generally positioned as a phenotypic modulator rather than a highly selective single target probe, and reported in vitro pharmacology is therefore typically summarized qualitatively with activity assessed across nanomolar to micromolar or low micromolar concentration windows depending on assay format, cell type, and endpoint sensitivity; in practical research settings it is commonly applied in vascular cell assays, genotoxicity batteries, bacterial mutation systems, and mouse based mechanistic studies to benchmark vasoactive responses, DNA damage associated outcomes, and safety signaling in early discovery programs, and the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.